Oruka Therapeutics' (ORKA) "Buy" Rating Reaffirmed at Guggenheim

Key Points

• Guggenheim reaffirmed its “Buy” rating on Oruka Therapeutics and set a $200 price target, implying approximately 93% upside from the prior close. Analysts overall maintain a “Moderate Buy” consensus with an average target of $134.30.
• Oruka shares closed at $103.47, near their 52-week high of $107.55, while the company reported a quarterly loss of $0.55 per share—$0.04 worse than analyst expectations.
• Institutional ownership stands at 56.44%, following major new positions including BlackRock’s approximately $475 million stake. Insiders sold 188,406 shares worth about $12 million over the past 90 days, primarily through pre-arranged trading plans.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Guggenheim in a report released on Tuesday,Benzinga reports. They presently have a $200.00 price target on the stock. Guggenheim's target price points to a potential upside of 93.28% from the stock's previous close.

Other research analysts have also issued reports about the company. BTIG Research reiterated a "buy" rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday. Barclays increased their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an "overweight" rating in a research report on Monday, April 27th. UBS Group boosted their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a research report on Wednesday, July 1st. HC Wainwright reaffirmed a "buy" rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $134.30.

Oruka Therapeutics Stock Performance

NASDAQ ORKA traded down $1.67 during trading on Tuesday, reaching $103.47. 50,193 shares of the company traded hands, compared to its average volume of 1,138,098. The stock's 50 day moving average price is $83.59 and its two-hundred day moving average price is $60.75. The company has a market cap of $6.24 billion, a price-to-earnings ratio of -53.29 and a beta of -0.34. Oruka Therapeutics has a 1-year low of $13.06 and a 1-year high of $107.55.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). Equities research analysts expect that Oruka Therapeutics will post -2.06 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the sale, the insider directly owned 32,718 shares of the company's stock, valued at approximately $2,266,703.04. This trade represents a 19.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Carl Dambkowski sold 105,000 shares of the business's stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00. Following the sale, the director owned 73,743 shares of the company's stock, valued at approximately $4,348,624.71. The trade was a 58.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 188,406 shares of company stock valued at $12,019,683 over the last ninety days. Company insiders own 23.49% of the company's stock.

Institutional Trading of Oruka Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORKA. E Fund Management Co. Ltd. bought a new stake in Oruka Therapeutics during the 2nd quarter worth about $579,000. BlackRock Inc. bought a new stake in shares of Oruka Therapeutics during the second quarter worth approximately $474,916,000. Deutsche Bank AG acquired a new position in Oruka Therapeutics in the second quarter valued at approximately $18,578,000. Persistent Asset Partners Ltd bought a new position in Oruka Therapeutics in the second quarter valued at approximately $674,000. Finally, Bank of New York Mellon Corp bought a new position in Oruka Therapeutics in the second quarter valued at approximately $13,407,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source